Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.

@article{Saini2011CosteffectivenessAC,
  title={Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention.},
  author={Sameer D. Saini and A. Mark Fendrick and James M. Scheiman},
  journal={Alimentary pharmacology & therapeutics},
  year={2011},
  volume={34 2},
  pages={243-51}
}
BACKGROUND Many patients with cardiovascular (CV) disease will stop aspirin (ASA) because of ASA-related dyspepsia. Proton pump inhibitor (PPI) co-therapy may reduce ASA-related dyspepsia, enhancing ASA adherence and improving CV outcomes. AIM To explore the impact of PPI co-therapy on CV outcomes in long-term, low-dose ASA users. METHODS We modified a previously published Markov model to assess the long-term impact of PPI co-therapy on CV and upper gastrointestinal bleeding (UGIB) outcomes… CONTINUE READING
14 Citations
59 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 14 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 59 references

Low-dose aspirin for secondary cardiovascular prevention – cardiovascular risks after its perioperative Cardiovascular benefits of proton pump inhibitor co-therapy

  • W Burger, JM Chemnitius, GD Kneissl, G. Rucker
  • Aliment Pharmacol Ther
  • 2011

Accf ⁄ Acg ⁄ Aha

  • NS Abraham, MA Hlatky, EM Antman
  • 2010

Similar Papers

Loading similar papers…